MUCINEX DM
LOE Approachingguaifenesin and dextromethorphan hydrobromide
NDAORALTABLET, EXTENDED RELEASE
Approved
Apr 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MUCINEX DM is an oral extended-release tablet combining guaifenesin (expectorant) and dextromethorphan hydrobromide (cough suppressant) for symptomatic relief of cough and chest congestion associated with cold or flu. It works by thinning mucus secretions while suppressing the cough reflex, making it an adjunct therapy for upper respiratory symptoms.
LOE Approaching
As loss of exclusivity approaches, the brand team is likely consolidating, with emphasis shifting toward line extensions, cost management, and preparation for generic competition.
Mechanism of Action
Pharmacologic Class:
Expectorant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career opportunities on MUCINEX DM are limited and focused on commercial and regulatory functions typical of mature OTC products. Working on this product offers experience in brand defense, retail marketing, and generic competition management, but limited visibility into innovation or high-growth initiatives.
Brand ManagerTrade Marketing Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.